Resistance Oncology ApS: Financial statements 2017
CVR: 36945125
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 51,356 and a net result of DKK 1,147,497. Equity in the 2017 report amounted to DKK -12,154.
- Gross Profit
- DKK 51,356
- Profit/Loss
- DKK 1,147,497
- Equity
- DKK -12,154
- Total Assets
- DKK 51,884
- Employees
- 0
Official annual report
Keep an eye on Resistance Oncology ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
Resistance Oncology ApS has published its interim report for the period July 1, 2015 – December 31, 2016.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.